Chronic myeloid leukemia in a patient treated with palbociclib and exemestane: a case report

This case underscores the pressing need for further research to enhance our understanding of the adverse events associated with treatment using CDK4/6 inhibitors, particularly concerning their effects on the hematological system. Additionally, it highlights the significance of long-term monitoring in clinical practice for patients receiving therapy with CDK4/6 inhibitors.